Pentixapharm Holding AG, an advanced clinical-stage biotech developing novel radiopharmaceuticals, presented extensive clinical data from independent investigator-initiated studies assessing Pentixapharm’s CXCR4-targeting diagnostic lead candidate, [68Ga] Ga-PentixaFor, at the ongoing Annual Congress of the European Association of Nuclear Medicine (EANM 2025) in Barcelona, Spain.
Four oral presentations and seven e-posters feature new data on [68Ga] Ga-PentixaFor PET/CT imaging in Primary Aldosteronism (PA) – a condition frequently underdiagnosed despite being one of the leading causes of secondary hypertension. These presentations include comparative clinical trial results, evaluating [68Ga] Ga-PentixaFor against adrenal venous sampling (AVS), the current invasive gold standard for subtyping PA. The data demonstrate the high potential of [68Ga] Ga-PentixaFor to significantly improve subtyping of patients, thereby enabling better therapy decisions, and more precise patient management in PA.
Complementing all these results in cardiovascular and endocrine disease, the scientific program at EANM 2025 also showcases the expanding role of Pentixapharm’s CXCR4-targeted platform in oncology. Among the highlights are first-in-human data on Pentixapharm’s therapeutic candidate [¹⁷⁷Lu] Lu-PentixaTher, in patients with bladder cancer. The early findings demonstrate initial signs of therapeutic activity, adding to the growing body of evidence supporting [¹⁷⁷Lu] Lu-PentixaTher as a precision treatment candidate for CXCR4-positive malignancies.
